<SEC-DOCUMENT>0001104659-24-071331.txt : 20240613
<SEC-HEADER>0001104659-24-071331.hdr.sgml : 20240613
<ACCEPTANCE-DATETIME>20240613165925
ACCESSION NUMBER:		0001104659-24-071331
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240613
DATE AS OF CHANGE:		20240613

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		241042001

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		203 787 7888

	MAIL ADDRESS:	
		STREET 1:		4 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2417251d2_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A INFORMATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section&nbsp;14(a)
of the </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant &thinsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Preliminary Proxy Statement</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><B>Confidential, for Use of the Commission Only (as permitted
by Rule&nbsp;14a-6(e)(2))</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Definitive Proxy Statement</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD><TD STYLE="text-align: justify">Definitive Additional Materials</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting Material Pursuant to &sect;240.14a-12</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 100%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Precipio, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Name of Registrant as Specified In Its Charter) </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check all boxes that apply):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD><TD STYLE="text-align: justify">No fee required.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&thinsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Fee paid previously with preliminary materials.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Fee computed on table in exhibit required by Item&nbsp;25(b)
per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="logo.jpg" ALT=""><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&thinsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>4 Science Park </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>New Haven, Connecticut 06511</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEW HAVEN, CT, (June 13, 2024) Specialty diagnostics
company <FONT STYLE="color: #165B8E"><U>Precipio, Inc.</U></FONT><U><FONT STYLE="color: #5A5A5A">&nbsp;</FONT><FONT STYLE="color: #165B8E">(NASDAQ:
PRPO)</FONT></U>, today announced that the company&rsquo;s 2024 Annual Meeting of Shareholders (&ldquo;Annual Meeting&rdquo;) was convened
and adjourned, without any business being conducted, due to lack of the required quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Message from Ilan Danieli, CEO:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During this process, we&rsquo;ve realized that
there are quite a few shareholders who didn&rsquo;t know whether their shares were voted on or not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you are not sure if your shares were voted,
you should be able to see that information on your broker portal when you log in. If you can't find that information, please reach out
to your broker and ask them - it's an easy and quick phone call and they will let you know right away.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If your shares were not voted &ndash; <B>PLEASE,
MAKE SURE THEY GET VOTED</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You can accomplish this in one of three easy ways
that will take no more than 60 seconds:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">Ask the broker to vote for your shares.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Request your 16-digit
                                            control number, and you can vote for the shares yourself by going to <FONT STYLE="color: Blue"><U>www.proxyvote.com</U></FONT>.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Log into your brokerage account and there should be a button
to vote the shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regardless of whether you vote for or against
the measures presented, what&rsquo;s important is to vote. As a shareholder, it is in YOUR BEST INTEREST that the company reaches a quorum
so that it avoids costly procedures to complete the annual shareholder meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A quorum consists of the presence
at the Annual Meeting either online during the live audio webcast or represented by proxy of the holders of a majority of the voting power
of our outstanding shares of common stock entitled to vote at the Annual Meeting. There were fewer than a majority of shares entitled
to vote present, either in person or by proxy at the Annual Meeting. The Annual Meeting, therefore, had no quorum, and accordingly, the
Annual Meeting has been adjourned. The Annual Meeting will resume with respect to all proposals at 9 a.m. Eastern Time on Friday, June
21, 2024, and will continue to be held virtually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The record date for determining
shareholders eligible to vote at the Annual Meeting will remain the close of business on April 19, 2024. Shareholders who have already
submitted a proxy do not need to vote again for the reconvened Annual Meeting, as the proxies submitted will remain valid. Shareholders
who have already submitted proxies and would like to change their vote with respect to any of the proposals can update their vote in the
manner set forth in the Definitive Proxy Statement. Your vote will be recorded at the Annual Meeting in accordance with your most recently
submitted proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Precipio&rsquo;s shareholders
as of close of business on the April 19, 2024 record date who have not yet voted are encouraged to vote online at www.proxyvote.com or
by telephone at 1-800-690-6903.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Voting on all proposals will
be open until the conclusion of Precipio&rsquo;s 2024 Annual Meeting on Friday, June 21, 2024. Votes Submitted through the Internet or
your broker must be submitted by 11:59&nbsp;p.m.,&nbsp;Eastern Time, on June 20, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please note: if your shares
are held in a brokerage account or by a bank or other holder of record, you are considered the &ldquo;beneficial owner&rdquo; of shares
held in &ldquo;street name.&rdquo; The proxy materials have been forwarded to you by your broker, bank or other nominee who is considered,
with respect to those shares, the stockholder of record. As the beneficial owner, you have the right to direct your broker, bank or other
holder of record on how to vote your shares by following their instructions for voting. Please refer to information from your bank, broker
or other nominee on how to submit your voting instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9;You may also vote at www.proxyvote.com.
You will need the 16-digit control number included on the Notice of Internet Availability of Proxy Materials or the proxy card.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the Definitive Proxy
Statement is available to shareholders on the Company&rsquo;s website and at the website maintained by the SEC at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Precipio shareholders as of
the April 19, 2024 record date for the Annual Meeting are invited to attend the virtual Annual Meeting by visiting www.virtualshareholdermeeting.com/PRPO2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Additional Information and where to find
it</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This material may be
deemed to be solicitation material in respect of the Annual Meeting to be reconvened and held on June 19, 2024. On April 29, 2024The
Company has filed a Definitive Proxy Statement and associated proxy card with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
in connection with the solicitation of proxies for the Annual Meeting. The Company, its directors, its executive officers and certain
other individuals set forth in the Definitive Proxy Statement will be deemed participants in the solicitation of proxies from stockholders
in respect of the Annual Meeting. Information regarding the names of the company&rsquo;s directors and executive officers and certain
other individuals and their respective interests in the Company has been included in the definitive proxy statement filed with the SEC
on April 29, 2024. Details containing the nominees of the Company&rsquo;s Board of Directors for election at the 2024 Annual Meeting
of Stockholders are included in the definitive proxy statement. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF THE COMPANY ARE URGED
TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO
AND ACCOMPANYING PROXY CARD, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. The Company&rsquo;s Definitive Proxy Statement and a form of
proxy have been mailed to stockholders of the Company. No changes have been made to the proposals to be voted on by shareholders at the
Annual Meeting Investors and stockholders can obtain a copy of the documents filed by the Company with the SEC, including the definitive
proxy statement, free of charge by visiting the SEC&rsquo;s website, <FONT STYLE="color: Blue"><U>www.sec.gov</U></FONT> and from the
Company&rsquo;s website <FONT STYLE="color: Blue"><U>www.precipiodx.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Precipio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1pt; background-color: white">Precipio
is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses
by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved
laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies
in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes
these technologies as proprietary products that serve the global laboratory community and further scales Precipio&rsquo;s reach to eradicate
misdiagnosis. For more information, please visit <FONT STYLE="color: Blue"><U>www.precipiodx.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Cautionary Note on
Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, including, among others, including other financial projections and potential market opportunity, plans and prospects.
Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per
share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements
based on management&rsquo;s estimates, beliefs, assumptions and projections. Words such as &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;expects,&rdquo;
 &ldquo;anticipates,&rdquo; &ldquo;will,&rdquo; &ldquo;targets,&rdquo; &ldquo;goals,&rdquo; &ldquo;projects,&rdquo; &ldquo;intends,&rdquo;
 &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; and variations on such
words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance,
are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and
uncertainties, and actual results could differ materially from those discussed. We caution investors not to place undue reliance on the
forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov,
for a discussion of these and other risks and uncertainties Important factors that could affect performance and cause results to differ
materially from management&rsquo;s expectations, or could affect the company&rsquo;s ability to achieve its strategic goals, includes
factors that are described in the sections entitled &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis&rdquo;
in the company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as updated from time to time in the company&rsquo;s
Securities and Exchange Commission filings. The company&rsquo;s forward-looking statements in this press release are based on management&rsquo;s
current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company
undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events
or otherwise, except as required by the federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #1155CC"><B><U>investors@precipiodx.com</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #1155CC">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222">+1-203-787-7888
Ext. 523</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #222222"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- 90# 2(  A$! Q$!_\0
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M2#K)/,W\E('Z5?/PZ\(LH!T2# ]&<?UKJ**GGEW"R.5_X5OX0_Z L7_?Q_\
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M]85510J@*H&  , "F03Q7-O'/"X>*50Z.O1E(R#4E1*5P1YK\.VV^-/'3')
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M )$BK3\'^'=2TGQCXIOKN$);7LX>W?>#O!9FZ#D8R.M+XT\/ZEJ_BCPI>64
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-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
